News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
37–55
Matches
55
Sources here
10
Companies here
1
Search results Stored financial headlines

Active search

55 matching headlines

Ticker or company: JSPRMain company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Stock Titan Market update Main company 🇺🇸 United States

Jasper Therapeutics (JSPR) COO buys non-voting convertible preferred shares

Jasper Therapeutics' Chief Operating Officer, Matthew E. Ros, purchased 881 shares of Non-Voting Convertible Preferred Stock on July 20, 2026, via a private placement. These preferred shares are convertible into 61 shares of Voting Common Stock each, subject to stockholder approval and a beneficial …

JSPR main company
Sharemaestro market context Price below Trend Line 52 weeks -73.0% JSPR stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com South Africa Market update Main company 🇺🇸 United States

Form 4 Jasper Therapeutics Inc For: 22 July By Investing.com

This article reports on a Form 4 filing for Jasper Therapeutics Inc. on July 22. It indicates that the company's stock symbol is JSPR, which experienced a -3.25% change. The content primarily consists of market data and related news beyond the immediate Form 4 …

JSPR main company
Sharemaestro market context Price below Trend Line 52 weeks -73.0% JSPR stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Deals and strategy Main company 🇺🇸 United States

Jasper Therapeutics (JSPR) COO discloses merger-converted option stakes

Jasper Therapeutics' COO, Matthew E. Ros, reported initial derivative holdings following Kira Pharmaceuticals' merger into a Jasper subsidiary. These holdings include options to purchase 103,204 shares of Jasper voting common stock and 92,278 shares of non

JSPR main company
Sharemaestro market context Price below Trend Line 52 weeks -73.0% JSPR stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Deals and strategy Main company 🇺🇸 United States

Jasper Therapeutics (JSPR) EVP outlines option and preferred stakes after Kira deal

Jasper Therapeutics EVP Wenru Song has reported her equity positions following the merger of Kira Pharmaceuticals into a Jasper subsidiary. Her holdings include converted Kira options for Jasper's Voting Common Stock and Non-Voting Convertible Preferred Stock, with varying exercise prices and full vesting. Additionally, …

JSPR main company
Sharemaestro market context Price below Trend Line 52 weeks -73.0% JSPR stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Deals and strategy Main company 🇺🇸 United States

Jasper Therapeutics (JSPR) director details common and preferred stake

Patrick J. Crutcher, a director at Jasper Therapeutics (JSPR), reported his holdings of 518,331 shares of Voting Common Stock and 463,452 shares of Non-Voting Convertible Preferred Stock. The preferred stock is convertible into 61 shares of common stock upon stockholder approval, subject to a …

JSPR main company
Sharemaestro market context Price below Trend Line 52 weeks -73.0% JSPR stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

Jasper Therapeutics (JSPR) director buys preferred stock, granted stock options

Patrick J. Crutcher, a director at Jasper Therapeutics, Inc. (JSPR), recently acquired 888 shares of Non-Voting Convertible Preferred Stock via a private placement on July 20, 2026. These preferred shares will convert into 61 shares of Voting Common Stock each, after stockholder approval, subject …

JSPR main company
Sharemaestro market context Price below Trend Line 52 weeks -73.0% JSPR stored weekly price path from 22 Aug 2025 to 14 Aug 2026
PharmaTimes Deals and strategy Main company 🇺🇸 United States

Jasper Therapeutics merges with Kira Pharmaceuticals

Jasper Therapeutics has completed an all-stock acquisition of Kira Pharmaceuticals, forming a combined entity focused on developing biologic agents for immunologically-driven conditions. The deal is backed by a $132 million private placement and an out-licensing agreement with Mirador Therapeutics, expected to fund operations through …

JSPR main company
Sharemaestro market context Price below Trend Line 52 weeks -73.0% JSPR stored weekly price path from 22 Aug 2025 to 14 Aug 2026
ad-hoc-news.de Guidance Main company 🇺🇸 United States

Jasper Therapeutics stock trades sideways as cash position and clinical pipeline shape outlook

Jasper Therapeutics (JSPR) is an early-stage biotech company trading on Nasdaq, with its stock performance closely tied to its cash reserves, burn rate, and the progress of its clinical pipeline. The company is developing CD117-targeted conditioning agents for hematopoietic stem cell transplantation and gene …

JSPR main company
Sharemaestro market context Price below Trend Line 52 weeks -73.0% JSPR stored weekly price path from 22 Aug 2025 to 14 Aug 2026
BioPharma Dive Deals and strategy Main company 🇺🇸 United States

Jasper gets a lifeline in merger with immune drugmaker Kira

Cash-strapped Jasper Therapeutics has merged with privately held Kira Pharmaceuticals in an all-stock acquisition, securing a $132 million private stock offering that extends its operational runway through 2028. This deal allows Jasper to rebound from previous setbacks and expand its pipeline with two immune …

JSPR main company
Sharemaestro market context Price below Trend Line 52 weeks -73.0% JSPR stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Benzinga Deals and strategy Main company 🇺🇸 United States

Jasper Closes Kira Deal, Extends Cash Runway

Jasper Therapeutics has completed its all-stock acquisition of Kira Pharmaceuticals, enhancing its pipeline of therapies for immune-mediated diseases. This merger, combined with a $132 million private placement, extends Jasper's cash runway through the second half of 2028. The company plans to advance several key …

JSPR main company
Sharemaestro market context Price below Trend Line 52 weeks -73.0% JSPR stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Benzinga Market update Main company 🇺🇸 United States

12 Health Care Stocks Moving In Friday's Intraday Session

This article lists 12 health care stocks experiencing significant price movements during Friday's intraday trading. It details six gainers, including Jasper Therapeutics and Kalaris Therapeutics, with their percentage increases, stock prices, and market capitalizations. The article also covers six losers, such as Agape ATP …

JSPR main company
Sharemaestro market context Price below Trend Line 52 weeks -73.0% JSPR stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Deals and strategy Main company 🇺🇸 United States

Patrick Crutcher appointed to Jasper Therapeutics board; Matthew Ros named COO

Jasper Therapeutics (JSPR) has announced two key appointments: Patrick Crutcher to its board of directors and Matthew Ros as Chief Operating Officer. These changes are effective immediately following the Effective Time on July 16, 2026, and are in accordance with a merger agreement. Both …

JSPR main company
Sharemaestro market context Price below Trend Line 52 weeks -73.0% JSPR stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Deals and strategy Main company 🇺🇸 United States

Jasper Therapeutics (NASDAQ: JSPR) buys Kira, adds $132M PIPE cash

Jasper Therapeutics (NASDAQ: JSPR) announced the all-stock acquisition of Kira Pharmaceuticals and concurrently secured $132 million in PIPE financing. This strategic move is expected to significantly dilute pre-transaction Jasper equity holders but aims to fund multiple clinical milestones and operating needs through the second …

JSPR main company
Sharemaestro market context Price below Trend Line 52 weeks -73.0% JSPR stored weekly price path from 22 Aug 2025 to 14 Aug 2026
FirstWord PHARMA Deals and strategy Main company 🇺🇸 United States

Jasper buys time with Kira merger and $132M PIPE lifeline

The article discusses Jasper's merger with Kira and a $132 million PIPE (Private Investment in Public Equity) lifeline. This strategic move aims to provide Jasper with additional resources and time, addressing financial challenges and enhancing its market position. The merger and investment are critical …

JSPR main company
Sharemaestro market context Price below Trend Line 52 weeks -73.0% JSPR stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Bitget Deals and strategy Main company 🇺🇸 United States

Jasper Therapeutics posts investor presentation on Kira merger, PIPE financing and immunology pipeline strategy

Jasper Therapeutics has released an investor presentation detailing its all-stock merger with Kira Pharmaceuticals, accompanied by a $132 million PIPE financing. The deal outlines an ownership split favoring legacy Kira holders and PIPE investors, with Jasper holders receiving a contingent value right. Proceeds from …

JSPR main company
Sharemaestro market context Price below Trend Line 52 weeks -73.0% JSPR stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Deals and strategy Main company 🇺🇸 United States

Jasper Therapeutics completes Kira acquisition, secures $132M financing to fund pipeline into H2 2028

Jasper Therapeutics has completed an all-stock acquisition of Kira Pharmaceuticals and concurrently secured $132 million in financing. This funding, along with proceeds from out-licensed assets, is expected to finance combined operations and multiple clinical milestones through the second half of 2028. The company plans …

JSPR main company
Sharemaestro market context Price below Trend Line 52 weeks -73.0% JSPR stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Deals and strategy Main company 🇺🇸 United States

Jasper Merger Brings Three Drug Candidates for Immune Disorders

Jasper Therapeutics has completed an all-stock acquisition of Kira Pharmaceuticals, creating a combined company focused on developing biologic therapies for immunologically-driven disorders. Concurrently, Jasper secured approximately $132 million in a private placement and out-licensed two assets for $12 million, extending its cash runway through …

JSPR main company
Sharemaestro market context Price below Trend Line 52 weeks -73.0% JSPR stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Moomoo Deals and strategy Main company 🇺🇸 United States

Press Release: Jasper Therapeutics Announces Merger With Kira Pharmaceuticals

Jasper Therapeutics and Kira Pharmaceuticals have announced a definitive merger agreement. The combined company will focus on advancing Kira's pipeline of complement-guided therapies for immune-mediated diseases, including a lead asset, KP104, nearing Phase 3 trials. The merger aims to create a clinical-stage biotechnology company …

JSPR main company
Sharemaestro market context Price below Trend Line 52 weeks -73.0% JSPR stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Deals and strategy Main company 🇺🇸 United States

Jasper Therapeutics (NASDAQ: JSPR) closes Kira merger and $132M preferred financing

Jasper Therapeutics (NASDAQ: JSPR) has completed its all-stock acquisition of Kira Pharmaceuticals and secured approximately $132 million in preferred stock financing. This merger combines Kira's complement-therapy assets (KP-104, KP-701) with Jasper's briquilimab program, creating a consolidated pipeline focused on immunologically-driven disorders. The financing, along …

JSPR main company
Sharemaestro market context Price below Trend Line 52 weeks -73.0% JSPR stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context